Multitarget therapy for induction treatment of lupus nephritis: a randomized trial
- PMID: 25383558
- DOI: 10.7326/M14-1030
Multitarget therapy for induction treatment of lupus nephritis: a randomized trial
Abstract
Background: Treatment of lupus nephritis (LN) remains challenging.
Objective: To assess the efficacy and safety of a multitarget therapy consisting of tacrolimus, mycophenolate mofetil, and steroid compared with intravenous cyclophosphamide and steroid as induction therapy for LN.
Design: 24-week randomized, open-label, multicenter study. (ClinicalTrials.gov: NCT00876616).
Setting: 26 renal centers in China.
Patients: Adults (aged 18 to 65 years) with biopsy-proven LN.
Intervention: Tacrolimus, 4 mg/d, and mycophenolate mofetil, 1.0 g/d, versus intravenous cyclophosphamide with a starting dose of 0.75 (adjusted to 0.5 to 1.0) g/m2 of body surface area every 4 weeks for 6 months. Both groups received 3 days of pulse methylprednisolone followed by a tapering course of oral prednisone therapy.
Measurements: The primary end point was complete remission at 24 weeks. Secondary end points included overall response (complete and partial remission), time to overall response, and adverse events.
Results: After 24 weeks of therapy, more patients in the multitarget group (45.9%) than in the intravenous cyclophosphamide group (25.6%) showed complete remission (difference, 20.3 percentage points [95% CI, 10.0 to 30.6 percentage points]; P < 0.001). The overall response incidence was higher in the multitarget group than in the intravenous cyclophosphamide group (83.5% vs. 63.0%; difference, 20.4 percentage points [CI, 10.3 to 30.6 percentage points]; P < 0.001), and the median time to overall response was shorter in the multitarget group (difference, -4.1 weeks [CI, -7.9 to -2.1 weeks]). Incidence of adverse events did not differ between the multitarget and intravenous cyclophosphamide groups (50.3% [91 of 181] vs. 52.5% [95 of 181]).
Limitation: The study was limited to 24 weeks of follow-up.
Conclusion: Multitarget therapy provides superior efficacy compared with intravenous cyclophosphamide as induction therapy for LN.
Primary funding source: National Basic Research Program of China, National Key Technology R&D Program.
Comment in
-
Lupus nephritis: Multitarget induction therapy for LN.Nat Rev Nephrol. 2015 Jan;11(1):3. doi: 10.1038/nrneph.2014.225. Epub 2014 Nov 25. Nat Rev Nephrol. 2015. PMID: 25421833 No abstract available.
-
Celebrating the ACP centennial: from the Annals archive.Ann Intern Med. 2015 Jan 6;162(1):70. doi: 10.7326/M14-2654. Ann Intern Med. 2015. PMID: 25560715 No abstract available.
Summary for patients in
-
Summaries for patients. Multitarget therapy for induction treatment of lupus nephritis.Ann Intern Med. 2015 Jan 6;162(1):I24. doi: 10.7326/P15-9000. Ann Intern Med. 2015. PMID: 25383607 No abstract available.
Similar articles
-
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.N Engl J Med. 2005 Nov 24;353(21):2219-28. doi: 10.1056/NEJMoa043731. N Engl J Med. 2005. PMID: 16306519 Clinical Trial.
-
Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.Nephrol Dial Transplant. 2012 Apr;27(4):1467-72. doi: 10.1093/ndt/gfr484. Epub 2011 Sep 13. Nephrol Dial Transplant. 2012. PMID: 21917733 Clinical Trial.
-
Summaries for patients. Multitarget therapy for induction treatment of lupus nephritis.Ann Intern Med. 2015 Jan 6;162(1):I24. doi: 10.7326/P15-9000. Ann Intern Med. 2015. PMID: 25383607 No abstract available.
-
Immunosuppressive treatment for proliferative lupus nephritis.Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4. Cochrane Database Syst Rev. 2018. PMID: 29957821 Free PMC article. Review.
-
Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.Drugs. 2012 Jul 30;72(11):1521-33. doi: 10.2165/11635030-000000000-00000. Drugs. 2012. PMID: 22818016 Review.
Cited by
-
Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy.Res Sq [Preprint]. 2024 Jan 23:rs.3.rs-3867933. doi: 10.21203/rs.3.rs-3867933/v1. Res Sq. 2024. PMID: 38343803 Free PMC article. Preprint.
-
Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps.J Clin Med. 2024 Jan 13;13(2):451. doi: 10.3390/jcm13020451. J Clin Med. 2024. PMID: 38256585 Free PMC article. Review.
-
Managing Lupus Nephritis in Children and Adolescents.Paediatr Drugs. 2024 Mar;26(2):145-161. doi: 10.1007/s40272-023-00609-3. Epub 2023 Dec 20. Paediatr Drugs. 2024. PMID: 38117412 Review.
-
The efficacy of immunosuppressive drugs induction therapy for lupus nephritis: a systematic review and network meta-analysis.Ren Fail. 2023;45(2):2290365. doi: 10.1080/0886022X.2023.2290365. Epub 2023 Dec 12. Ren Fail. 2023. PMID: 38087473 Free PMC article. Review.
-
Lupus Nephritis in Children: Novel Perspectives.Medicina (Kaunas). 2023 Oct 16;59(10):1841. doi: 10.3390/medicina59101841. Medicina (Kaunas). 2023. PMID: 37893559 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical